Document is current
Any future updates will be listed below
-
Authors
Lund, Leah M. https://orcid.org/0009-0003-8358-3909
Marchi, Angelina N.
Alderfer, Laura
Hall, Eva
Hammer, Jacob https://orcid.org/0009-0006-1805-9942
Moremen, Riley
Asilebo, Ijeoma
Trull, Keelan J.
Hanjaya-Putra, Donny https://orcid.org/0000-0002-5403-544X
White, Katharine A. https://orcid.org/0000-0002-5831-1886
-
Funding
Funding for this research was provided by:
Henry Luce Foundation
Mike and Josie Harper Cancer Research Institute
DH | National Institute for Health Research (1DP2CA260416-01, 1R35-GM-143055)
Walther Cancer Foundation
American Cancer Society (IRG-17-182-04)
American Heart Association (19-CDA-34630012)
- License Information
-
More Information
Article History
Received: 9 July 2024
Revised: 25 July 2025
Accepted: 1 September 2025
First Online: 13 October 2025
Competing interests
: The authors declare no competing interests.
: All of the described work was performed on commercially-available human cell lines that were then modified for stable transgene expression or genetic knockout. No patient data or human subjects were used. All work was conducted under an authorized protocol approved by the University of Notre Dame Institutional Biosafety Committee (22-08-7339). All methods were performed in accordance with the relevant guidelines and regulations.
